![](https://mcb.berkeley.edu/sites/mcb.berkeley.edu/files/styles/article__200x200_/public/images/articles/Schaffer_9-19-17.jpg?itok=dlz2SV5L)
4D Molecular Therapeutics, co-founded by MCB & BioEngineering Professor David Schaffer has received $3 million in funding from Cystic Fibrosis Foundation Therapeutics Inc.
4D Molecular Therapeutics is a developer and manufacturer of gene therapeutic products. The funding will help them begin clinical trials of a new gene therapy treatment, 4D-710, on cystic fibrosis patients.